As a Professor of Oncology at Roswell Park Cancer Institute in Buffalo, New York, Mikhail Blagosklonny, MD, Ph.D. conducts research focusing on new anticancer strategies, including cell cyclotherapy. While Dr. Blagosklonny’s interests are wide-ranging, he is specifically interested in exploiting cell cycle modulators to protect non-cancerous cells from the perniciousness of chemotherapy by stopping the growth of normal cells so that cycle-dependent chemotherapy will target only growing cancer cells. On April 15, 2009, when Dr. Blagosklonny was recruited for his position, the Senior Vice-President of Basic Science at the Roswell Park Cancer Institute noted that the Institute shared Blagosklonny’s goal of protecting of non-cancerous cells from the effects of chemotherapy. See: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531
After graduation from the prestigious First Pavlov State Medical University of St. Petersburg, Mikhail Blagosklonny came to the New York Medical College, taking a position as associate professor of medicine. He went on to become a senior scientist for seven years at the Ordway Research Institute, which recruited the world’s best scientific minds to work on finding a cure for cancer and other diseases, before accepting the position to the Roswell Park Cancer Institute.
Blagosklonny is the editor-in-chief of Aging, a medical journal devoted to gerontology and senescence and Cell Cycle, a scientific journal focusing on cellular biology. Mikhail Blagoskloony is also the co-editor-in-chief of Oncotarget, an oncology-related medical journal. A prolific author, Blagosklonny has published more than 270 papers in medical and scientific journals.
During his research into tumor suppressors at the Roswell Park Cancer Institute, Mikhail Blagosklonny became a passionate proponent rapamycin, a drug which he believes will slow the aging process, since it slows tumor growth. He feels to strongly about rapamycin’s anti-aging abilities that Blagosklonny tried the drug himself. Colleagues were skeptical of his theory until a National Institutes of Health-funded study validated his theory by proving that rapamycin helped mice to live longer.
Read more about Mikhail Blagosklonny Research Gate